NEW YORK--(BUSINESS WIRE)--Foresight Biotherapeutics announced today the formation of its scientific advisory board to provide guidance to the company for the development of it’s lead product FST-100, a novel formulation of dexamethasone that includes povidone-iodine. Foresight’s Scientific Advisory Board is comprised of leaders in the field of Ophthalmology. These highly regarded experts will advise the company on its clinical programs, regulatory strategy and provide strategic guidance to support the development of FST-100 in multiple indications.
